Erdafitinib

Definition

An orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. Upon oral administration, erdafitinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways and thus the inhibition of tumor cell proliferation and tumor cell death in FGFR-overexpressing tumor cells. FGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival.

Also known as 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-, Balversa, ERDAFITINIB, JNJ 42756493, JNJ-42756493, JNJ42756493 — per NCIT

Also identified as

• ATC L01EN01 per RXNORM
• NCIT NCIT:C103273 per NCIT
• SCTID 787731007 per RXNORM
• SCTID 787742003 per RXNORM
• UNII 890E37NHMV per RXNORM

Indications